The latest European health & wellness business news: Probi partners with Swedish beauty firm Oriflame for probiotic launch; retailer Holland & Barrett enters the Chinese market with Alibaba's Tmall; and Enzymatica sees ColdZyme growth potential on Amazon.

Colgate is “not in a hurry” to make deals with valuations high for businesses it would target, says CEO Noel Wallace. Increasing commodity costs and rising inflation have the company prioritizing growth on existing businesses.

First Response pregnancy test sales didn’t decline during the pandemic as the underlying strength of the economy doesn’t slow consumer interest in expanding their families, says Church & Dwight CEO Matthew Farrell.

Harbor-UCLA Center for Clinical Pharmacology director Eric Brass says FDA should change DFL requirements, considering container labels as part of OTC labeling and reconsidering what information should be included on labels and threshold for consumer comprehension of labels.

CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.

The latest global health and wellness industry appointments: Stada hires Uriach's Roura to lead Spanish OTC business; CHPA elects J&J's Goodridge; Valbiotis brings in Ipsen's Bessy; and Mannatech's Bala joins DSA's board.

Colgate is “not in a hurry” to make deals with valuations high for businesses it would target, says CEO Noel Wallace. Increasing commodity costs and rising inflation have the company prioritizing growth on existing businesses.

First Response pregnancy test sales didn’t decline during the pandemic as the underlying strength of the economy doesn’t slow consumer interest in expanding their families, says Church & Dwight CEO Matthew Farrell.

Both firms announce agreement for Prestige to pay Akorn $230m cash for TheraTear, Diabetic Tussin and Zostrix OTCs and MagOx and Multi-betic supplements. Akorn says the agreement is "to sell its Consumer Health business,” even though it retains two consumer brands.

Health, beauty and wellness industry stakeholders believe Lina Khan’s appointment increases chances FTC will aggressively enforce against e-commerce giant Amazon. Agency movement alleging antitrust against Amazon could impact the pricing and sales of products online.

Cannabinoid products have been available in US since at least 2012, when states began legalizing cannabis, but the earliest USPTO is recognizing submissions for those marks is December 2018 and it won’t register trademarks until FDA allows lawful use of the ingredients in non-drug products.

Decisions in US Circuit and District courts for District of Columba are on complaint by Rx drug firm MediNatura, but should resonate for OTC homeopathic firms as well as all businesses across the sector. MediNatura appealed district ruling rejecting request for injunction against FDA’s withdrawal of 1988 homeopathic CPG.